Catalyst Biosciences Selects Drug Development Candidate In Factor VIIa Program For Hemophilia
May 15th 2008Drug InformationBlood
Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. CB 813 was created using Catalyst’s proprietary therapeutic protease platform technologies and know-how.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
